58 / 69
58
30.
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani
M, Cervantes F, et al. Imatinib compared with interferon
and low-dose cytarabine for newly diagnosed chronic-
phase chronic myeloid leukemia. N Engl J Med
2003;348:994-1004.
31.
Aguayo A, Couban S. State-of-the-art in the management
of chronic myelogenous leukemia in the era of the tyrosine
kinase inhibitors: evolutionary trends in diagnosis,
monitoring and treatment. Leuk Lymphoma 2009; 50
Suppl 2:1-8.
32.
Bonifazi F, De Vivo A, Rosti G, Tiribelli M, Russo D,
Trabacchi E, et al. Testing Sokal's and the new prognostic
score for chronic myeloid leukaemia treated with alpha-
interferon. Italian Cooperative Study Group on Chronic
Myeloid Leukaemia. Br J Haematol 2000;111:587-95.
33.
Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini
FE, et al. Changes in the dynamics of the excess mortality
rate in chronic phase-chronic myeloid leukemia over 1990-
2007: a population study. Blood 2011;118:4331-7.
34.
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian
H, Gattermann N, et al. Five-year follow-up of patients
receiving imatinib for chronic myeloid leukemia. N Engl J
Med 2006;355:2408-17.
35.
Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit
WM, Kersten MJ, et al. Efficacy of escalated imatinib
combined with cytarabine in newly diagnosed patients
with
chronic
myeloid
leukemia.
Haematologica
2010;95:914-21.
36.
Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge
DE, Nevill TJ, et al. Cytogenetic and molecular responses
to standard-dose imatinib in chronic myeloid leukemia are
correlated with Sokal risk scores and duration of therapy
but not trough imatinib plasma levels. Leuk Res
2009;33:271-5.